See more : PT Bank Central Asia Tbk (BBCA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of CYBERDYNE Inc. (CYBQF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CYBERDYNE Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Sands China Ltd. (1928.HK) Income Statement Analysis – Financial Results
- ONEX Corporation (5987.T) Income Statement Analysis – Financial Results
- Omeros Corporation (OMER) Income Statement Analysis – Financial Results
- JTEC Corporation (2479.T) Income Statement Analysis – Financial Results
- Beijer Alma AB (publ) (BEIA-B.ST) Income Statement Analysis – Financial Results
CYBERDYNE Inc. (CYBQF)
About CYBERDYNE Inc.
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains equipment and systems for medical and warfare in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; and Acoustic X, a high speed light pulse LED array light source that enables real time photoacoustic imaging. It also provides Cybernics Treatment, a treatment that uses HAL to enhance/regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; HAL FIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes' brain-nerve functions; and Neuro HALFIT for enhancement of physical functions. In addition, the company is involved in the provision of rescue supports in disaster sites, and heavy labor supports for factories and plants; and entertainment business. The company was incorporated in 2004 and is headquartered in Tsukuba, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.35B | 3.29B | 1.88B | 1.79B | 1.71B | 1.71B | 1.73B | 1.65B | 1.26B | 631.28M | 456.38M |
| Cost of Revenue | 1.96B | 1.50B | 591.00M | 492.00M | 481.00M | 481.00M | 523.00M | 570.99M | 401.12M | 359.80M | 245.99M |
| Gross Profit | 2.39B | 1.79B | 1.28B | 1.30B | 1.23B | 1.23B | 1.21B | 1.08B | 863.78M | 271.48M | 210.39M |
| Gross Profit Ratio | 54.96% | 54.45% | 68.48% | 72.54% | 71.85% | 71.85% | 69.73% | 65.39% | 68.29% | 43.00% | 46.10% |
| Research & Development | 877.00M | 735.00M | 689.00M | 812.00M | 998.00M | 998.00M | 834.00M | 902.87M | 1.00B | 983.28M | 716.17M |
| General & Administrative | 3.25B | 2.41B | 1.47B | 1.65B | 1.45B | 1.45B | 1.39B | 1.35B | 1.15B | 1.05B | 648.46M |
| Selling & Marketing | 0.00 | 671.00M | 535.00M | 309.00M | 227.00M | 195.00M | 213.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.25B | 2.41B | 1.47B | 1.65B | 1.45B | 1.45B | 1.39B | 1.35B | 1.15B | 1.05B | 648.46M |
| Other Expenses | 283.00M | -109.00M | -105.00M | -98.00M | -366.00M | -291.00M | -256.00M | 1.23B | 667.87M | 1.06B | 579.14M |
| Operating Expenses | 4.41B | 2.94B | 1.98B | 2.34B | 2.06B | 2.06B | 1.86B | 2.25B | 2.16B | 2.04B | 1.36B |
| Cost & Expenses | 6.37B | 4.44B | 2.57B | 2.83B | 2.54B | 2.54B | 2.39B | 2.82B | 2.56B | 2.40B | 1.61B |
| Interest Income | 543.00M | 1.31B | 770.00M | 1.18B | 239.00M | 239.00M | 13.00M | 8.90M | 32.85M | 2.83M | 372.00K |
| Interest Expense | 482.00M | 193.00M | 2.00M | 100.00M | 15.00M | 15.00M | 6.00M | 8.00M | 46.14M | 18.84M | 4.97M |
| Depreciation & Amortization | 677.00M | 627.00M | 482.00M | 463.00M | 492.00M | 436.00M | 399.00M | 335.00M | 280.30M | 202.30M | 179.67M |
| EBITDA | -758.00M | 873.00M | -482.00M | 873.00M | -179.00M | -397.00M | -284.00M | -304.00M | -1.01B | -1.56B | -975.00M |
| EBITDA Ratio | -17.41% | 18.21% | 27.41% | 33.93% | -10.47% | -10.47% | -15.45% | 18.69% | -24.60% | -94.93% | -92.62% |
| Operating Income | -2.02B | -1.15B | -700.00M | -1.04B | -830.00M | -830.00M | -659.00M | -1.17B | -1.29B | -1.77B | -1.15B |
| Operating Income Ratio | -46.35% | -34.81% | -37.33% | -57.98% | -48.57% | -48.57% | -38.14% | -71.04% | -102.15% | -279.77% | -252.92% |
| Total Other Income/Expenses | 877.00M | 1.20B | 311.00M | 1.11B | 921.00M | 261.00M | -13.00M | 524.12M | 582.05M | 863.22M | 475.69M |
| Income Before Tax | -1.14B | 53.00M | 408.00M | 91.00M | -569.00M | -569.00M | -672.00M | -782.91M | -710.08M | -902.90M | -678.55M |
| Income Before Tax Ratio | -26.21% | 1.61% | 21.76% | 5.08% | -33.29% | -33.29% | -38.89% | -47.45% | -56.14% | -143.03% | -148.68% |
| Income Tax Expense | 507.00M | 446.00M | 479.00M | 240.00M | 74.00M | 74.00M | 6.00M | 6.42M | 11.17M | 11.65M | 9.62M |
| Net Income | -1.48B | -298.00M | -59.00M | -152.00M | -632.00M | -632.00M | -673.00M | -789.33M | -718.06M | -915.89M | -688.17M |
| Net Income Ratio | -33.90% | -9.06% | -3.15% | -8.48% | -36.98% | -36.98% | -38.95% | -47.84% | -56.77% | -145.09% | -150.79% |
| EPS | -6.99 | -1.39 | -0.27 | -0.71 | -2.94 | -2.94 | -3.13 | -3.69 | -3.53 | -4.74 | -3.95 |
| EPS Diluted | -6.99 | -1.39 | -0.27 | -0.71 | -2.94 | -2.94 | -3.13 | -3.69 | -3.53 | -4.74 | -3.95 |
| Weighted Avg Shares Out | 211.13M | 214.71M | 215.13M | 215.14M | 215.14M | 215.05M | 215.05M | 213.82M | 203.28M | 193.31M | 174.26M |
| Weighted Avg Shares Out (Dil) | 211.13M | 214.71M | 215.13M | 215.14M | 215.14M | 215.05M | 215.05M | 213.82M | 203.28M | 193.31M | 174.26M |
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
Source: https://incomestatements.info
Category: Stock Reports